TY  - JOUR
T1  - Plasma Arginine Levels as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Insights from the CCTG CO.26 Trial
A1  - Hiroshi Kenji Nakamura
A1  - Takashi Akira Sato
A1  - Saskia Anna Mueller
A1  - Lukas Stefan Vogel
JF  - Archive of International Journal of Cancer and Allied Science
JO  - Arch Int J Cancer Allied Sci
SN  - 3108-4834
Y1  - 2023
VL  - 3
IS  - 2
DO  - 10.51847/SAhCUBE1Ao
SP  - 199
EP  - 205
N2  - Nutritional deprivation serves as a strategy for cancer cells to avoid detection by the immune system. Arginine (ARG), an amino acid with important roles in immune regulation, influences T-cell function and the body's defense against tumors. Low levels of ARG within the tumor surroundings can hinder T-cell effectiveness, while increasing ARG availability might boost anti-cancer immune responses.In this exploratory follow-up analysis of the randomized phase II CO.26 study, researchers assessed whether blood levels of ARG could help forecast treatment outcomes with immune checkpoint inhibitors (ICI) in individuals with microsatellite-stable metastatic colorectal cancer (mCRC) that no longer responds to standard therapies.The CO.26 study randomized patients with treatment-refractory metastatic colorectal cancer to receive either the combination of durvalumab and tremelimumab (D+T) or best supportive care (BSC). Baseline plasma arginine (ARG) concentrations were quantified from pre-treatment blood samples using high-performance liquid chromatography with tandem mass spectrometry. Patients were divided into two groups—ARG-high (≥10,700 ng/mL) and ARG-low (
UR  - https://smerpub.com/article/plasma-arginine-levels-as-predictive-biomarkers-of-response-to-immune-checkpoint-inhibitors-in-metas-okrwk7g7ysvyg4e
ER  -